BackgroundIncontinentia Pigmenti (IP) is a rare X-linked dominant genetic disorder with an estimated incidence of 1 in 40,000 live births. It is a systemic disease caused by mutations in the IKBKG gene (also known as NEMO) located on Xq28. [1] Mutations in this gene disrupt the normal function of NEMO, diminishing its ability to modulate NF-kB. This leads to multiple downstream effects involving regulation of inflammation, cell survival, distribution of melanin, and other tissue development. IP almost exclusively affects females, with non-lethal NEMO mutations in hemizygous XY male patients being extremely rare. [2] The disorder is characterized by cutaneous, dental, ocular, and neurological abnormalities due to mutations primarily affecting tissues derived from mesoderm and ectoderm during